Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Wang, L.; Li, X.; Shen, H.; Mao, N.; Wang, H.; Cui, L.; Cheng, Y.; Fan, J.
    Bacterial IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes as a potential therapy for IgA nephropathy (2016), Sci. Rep., 6, 30964 .
    View publication on PubMedView publication on EuropePMC

Application

EC Number Application Comment Organism
3.4.21.72 medicine IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes is a potential therapy for IgA nephropathy Haemophilus influenzae
3.4.21.72 medicine IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes is a potential therapy for IgA nephropathy Neisseria gonorrhoeae
3.4.21.72 medicine IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes is a potential therapy for IgA nephropathy Neisseria meningitidis

Natural Substrates/ Products (Substrates)

EC Number Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
3.4.21.72 immunglobulin A1 + H2O Haemophilus influenzae
-
 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O Neisseria gonorrhoeae
-
 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O Neisseria meningitidis
-
 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O Neisseria gonorrhoeae ATCC 49226
-
 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O Haemophilus influenzae ATCC 10211
-
 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O Haemophilus influenzae ATCC 49247
-
 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O Neisseria meningitidis ATCC 13090
-
 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 additional information Haemophilus influenzae IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN ?
-
 ?
3.4.21.72 additional information Neisseria gonorrhoeae IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN ?
-
 ?
3.4.21.72 additional information Neisseria meningitidis IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN ?
-
 ?
3.4.21.72 additional information Haemophilus influenzae immunglobulin A1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agimmunglobulin A1 also exists as circulating immunglobulin A1-immunglobulin G immune complexes in patients with IgAN ?
-
 ?
3.4.21.72 additional information Neisseria gonorrhoeae ATCC 49226 IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN ?
-
 ?
3.4.21.72 additional information Haemophilus influenzae ATCC 10211 IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN ?
-
 ?
3.4.21.72 additional information Haemophilus influenzae ATCC 10211 immunglobulin A1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agimmunglobulin A1 also exists as circulating immunglobulin A1-immunglobulin G immune complexes in patients with IgAN ?
-
 ?
3.4.21.72 additional information Haemophilus influenzae ATCC 49247 IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN ?
-
 ?
3.4.21.72 additional information Haemophilus influenzae ATCC 49247 immunglobulin A1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agimmunglobulin A1 also exists as circulating immunglobulin A1-immunglobulin G immune complexes in patients with IgAN ?
-
 ?
3.4.21.72 additional information Neisseria meningitidis ATCC 13090 IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN ?
-
 ?

Organism

EC Number Organism UniProt Comment Textmining
3.4.21.72 Haemophilus influenzae
-
-
-
3.4.21.72 Haemophilus influenzae ATCC 10211
-
-
-
3.4.21.72 Haemophilus influenzae ATCC 49247
-
-
-
3.4.21.72 Neisseria gonorrhoeae
-
-
-
3.4.21.72 Neisseria gonorrhoeae ATCC 49226
-
-
-
3.4.21.72 Neisseria meningitidis
-
-
-
3.4.21.72 Neisseria meningitidis ATCC 13090
-
-
-

Purification (Commentary)

EC Number Purification (Comment) Organism
3.4.21.72 native enzyme by hydrophobic interaction chromatography, ultrafiltration, anion exchange chromatography, dialysis, gel filtration, and again ultrafiltration Haemophilus influenzae
3.4.21.72 native enzyme by hydrophobic interaction chromatography, ultrafiltration, anion exchange chromatography, dialysis, gel filtration, and again ultrafiltration Neisseria gonorrhoeae
3.4.21.72 native enzyme by hydrophobic interaction chromatography, ultrafiltration, anion exchange chromatography, dialysis, gel filtration, and again ultrafiltration Neisseria meningitidis

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
3.4.21.72 aberrantly glycosylated immunglobulin A1 + H2O pathogenic human aberrantly glycosylated IgA1 Haemophilus influenzae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 aberrantly glycosylated immunglobulin A1 + H2O pathogenic human aberrantly glycosylated IgA1 Neisseria gonorrhoeae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 aberrantly glycosylated immunglobulin A1 + H2O pathogenic human aberrantly glycosylated IgA1 Neisseria meningitidis immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 aberrantly glycosylated immunglobulin A1 + H2O pathogenic human aberrantly glycosylated immunglobulin A1 Haemophilus influenzae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 aberrantly glycosylated immunglobulin A1 + H2O pathogenic human aberrantly glycosylated IgA1 Neisseria gonorrhoeae ATCC 49226 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 aberrantly glycosylated immunglobulin A1 + H2O pathogenic human aberrantly glycosylated IgA1 Neisseria meningitidis ATCC 13090 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 degalactosylated IgA1 + H2O artificial substrate, high activity Neisseria meningitidis immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 degalactosylated immunglobulin A1 + H2O artificial substrate, high activity Haemophilus influenzae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 degalactosylated immunglobulin A1 + H2O artificial substrate, high activity Neisseria gonorrhoeae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 desialylated and degalactosylated immunglobulin A1 + H2O artificial substrate, high activity Haemophilus influenzae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 desialylated and degalactosylated immunglobulin A1 + H2O artificial substrate, high activity Neisseria gonorrhoeae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 desialylated and degalactosylated immunglobulin A1 + H2O artificial substrate, high activity Neisseria meningitidis immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 desialylated IgA1 + H2O artificial substrate Haemophilus influenzae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 desialylated IgA1 + H2O artificial substrate Neisseria gonorrhoeae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 desialylated immunglobulin A1 + H2O artificial substrate Haemophilus influenzae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 desialylated immunglobulin A1 + H2O artificial substrate Neisseria meningitidis immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 desialylated/degalactosylated immunglobulin A1 + H2O artificial substrate, high activity Haemophilus influenzae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O
-
 Haemophilus influenzae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O
-
 Neisseria gonorrhoeae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O
-
 Neisseria meningitidis immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O human myeloma IgA1 Haemophilus influenzae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O human myeloma IgA1 Neisseria gonorrhoeae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O human myeloma IgA1 Neisseria meningitidis immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O human myeloma immunglobulin A1 Haemophilus influenzae immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O
-
 Neisseria gonorrhoeae ATCC 49226 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O human myeloma IgA1 Neisseria gonorrhoeae ATCC 49226 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O
-
 Haemophilus influenzae ATCC 10211 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O
-
 Haemophilus influenzae ATCC 49247 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O
-
 Neisseria meningitidis ATCC 13090 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 immunglobulin A1 + H2O human myeloma IgA1 Neisseria meningitidis ATCC 13090 immunglobulin Fc + immunglobulin Fd
-
 ?
3.4.21.72 additional information IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN Haemophilus influenzae ?
-
 ?
3.4.21.72 additional information IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN Neisseria gonorrhoeae ?
-
 ?
3.4.21.72 additional information IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN Neisseria meningitidis ?
-
 ?
3.4.21.72 additional information immunglobulin A1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agimmunglobulin A1 also exists as circulating immunglobulin A1-immunglobulin G immune complexes in patients with IgAN Haemophilus influenzae ?
-
 ?
3.4.21.72 additional information the enzyme activity is several fold higher with artificial substrates, degalactosylated IgA1 and desialylated/degalactosylated IgA1, as compared to the wild-type IgA1 substrate, while the activity with artificial desialylated IgA1 is reduced Haemophilus influenzae ?
-
 ?
3.4.21.72 additional information the enzyme activity is several fold higher with artificial substrates, degalactosylated IgA1 and desialylated/degalactosylated IgA1, as compared to the wild-type IgA1 substrate, while the activity with artificial desialylated IgA1 is reduced Neisseria gonorrhoeae ?
-
 ?
3.4.21.72 additional information the enzyme activity is several fold higher with artificial substrates, degalactosylated IgA1 and desialylated/degalactosylated IgA1, as compared to the wild-type IgA1 substrate, while the activity with artificial desialylated IgA1 is reduced Neisseria meningitidis ?
-
 ?
3.4.21.72 additional information the enzyme activity is several fold higher with artificial substrates, degalactosylated immunglobulin A1 and desialylated/degalactosylated immunglobulin A1, as compared to the wild-type immunglobulin A1 substrate, while the activity with artificial desialylated immunglobulin A1 is reduced Haemophilus influenzae ?
-
 ?
3.4.21.72 additional information IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN Neisseria gonorrhoeae ATCC 49226 ?
-
 ?
3.4.21.72 additional information the enzyme activity is several fold higher with artificial substrates, degalactosylated IgA1 and desialylated/degalactosylated IgA1, as compared to the wild-type IgA1 substrate, while the activity with artificial desialylated IgA1 is reduced Neisseria gonorrhoeae ATCC 49226 ?
-
 ?
3.4.21.72 additional information IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN Haemophilus influenzae ATCC 10211 ?
-
 ?
3.4.21.72 additional information immunglobulin A1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agimmunglobulin A1 also exists as circulating immunglobulin A1-immunglobulin G immune complexes in patients with IgAN Haemophilus influenzae ATCC 10211 ?
-
 ?
3.4.21.72 additional information the enzyme activity is several fold higher with artificial substrates, degalactosylated IgA1 and desialylated/degalactosylated IgA1, as compared to the wild-type IgA1 substrate, while the activity with artificial desialylated IgA1 is reduced Haemophilus influenzae ATCC 10211 ?
-
 ?
3.4.21.72 additional information the enzyme activity is several fold higher with artificial substrates, degalactosylated immunglobulin A1 and desialylated/degalactosylated immunglobulin A1, as compared to the wild-type immunglobulin A1 substrate, while the activity with artificial desialylated immunglobulin A1 is reduced Haemophilus influenzae ATCC 10211 ?
-
 ?
3.4.21.72 additional information IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN Haemophilus influenzae ATCC 49247 ?
-
 ?
3.4.21.72 additional information immunglobulin A1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agimmunglobulin A1 also exists as circulating immunglobulin A1-immunglobulin G immune complexes in patients with IgAN Haemophilus influenzae ATCC 49247 ?
-
 ?
3.4.21.72 additional information the enzyme activity is several fold higher with artificial substrates, degalactosylated IgA1 and desialylated/degalactosylated IgA1, as compared to the wild-type IgA1 substrate, while the activity with artificial desialylated IgA1 is reduced Haemophilus influenzae ATCC 49247 ?
-
 ?
3.4.21.72 additional information the enzyme activity is several fold higher with artificial substrates, degalactosylated immunglobulin A1 and desialylated/degalactosylated immunglobulin A1, as compared to the wild-type immunglobulin A1 substrate, while the activity with artificial desialylated immunglobulin A1 is reduced Haemophilus influenzae ATCC 49247 ?
-
 ?
3.4.21.72 additional information IgA1 exists in forms of monomer, dimer, and oligomer (or polymer) in the physiological conditions and agIgA1 also exists as circulating IgA1-IgG immune complexes in patients with IgAN Neisseria meningitidis ATCC 13090 ?
-
 ?
3.4.21.72 additional information the enzyme activity is several fold higher with artificial substrates, degalactosylated IgA1 and desialylated/degalactosylated IgA1, as compared to the wild-type IgA1 substrate, while the activity with artificial desialylated IgA1 is reduced Neisseria meningitidis ATCC 13090 ?
-
 ?

Synonyms

EC Number Synonyms Comment Organism
3.4.21.72 IgA protease
-
 Haemophilus influenzae
3.4.21.72 IgA protease
-
 Neisseria gonorrhoeae
3.4.21.72 IgA protease
-
 Neisseria meningitidis

General Information

EC Number General Information Comment Organism
3.4.21.72 physiological function the bacteria-derived IgA protease is capable of degrading the pathogenic human agIgA1 and derived immune complexes in vitro and in vivo. Mesangial deposition of aberrantly glycosylated IgA1 (agIgA1) and its immune complexes is a key pathogenic mechanism of IgA nephropathy (IgAN) in humans. The bacteria-derived IgA protease also can efficiently degrade the deposited IgA1-IgG immune complexes in a passive mouse model of IgAN Haemophilus influenzae
3.4.21.72 physiological function the bacteria-derived IgA protease is capable of degrading the pathogenic human agIgA1 and derived immune complexes in vitro and in vivo. Mesangial deposition of aberrantly glycosylated IgA1 (agIgA1) and its immune complexes is a key pathogenic mechanism of IgA nephropathy (IgAN) in humans. The bacteria-derived IgA protease also can efficiently degrade the deposited IgA1-IgG immune complexes in a passive mouse model of IgAN Neisseria gonorrhoeae
3.4.21.72 physiological function the bacteria-derived IgA protease is capable of degrading the pathogenic human agIgA1 and derived immune complexes in vitro and in vivo. Mesangial deposition of aberrantly glycosylated IgA1 (agIgA1) and its immune complexes is a key pathogenic mechanism of IgA nephropathy (IgAN) in humans. The bacteria-derived IgA protease also can efficiently degrade the deposited IgA1-IgG immune complexes in a passive mouse model of IgAN Neisseria meningitidis
3.4.21.72 physiological function the bacteria-derived IgA protease is capable of degrading the pathogenic human agimmunglobulin A1 and derived immune complexes in vitro and in vivo. Mesangial deposition of aberrantly glycosylated immunglobulin A1 (agIgA1) and its immune complexes is a key pathogenic mechanism of IgA nephropathy (IgAN) in humans. The bacteria-derived IgA protease also can efficiently degrade the deposited IgA1-IgG immune complexes in a passive mouse model of IgAN Haemophilus influenzae